Mobile

A 26 week randomised, open labelled, parallel group, multi-national, treat-to-target trial comparing efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin ver...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-001050-40

A 26 week randomised, open labelled, parallel group, multi-national, treat-to-target trial comparing efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin versus sitagliptin and metformin with or without sulphonylurea, in subjects with type 2 diabetes

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To compare glycaemic control, measured as HbA1c, of insulin detemir given once daily in combination with sitagliptin and metformin versus sitagliptin and metformin ± SU after a 26-week treatment period in subjects with type 2 diabetes inadequately controlled on metformin treatment with or without other OADs.

Critère d'inclusion

  • Type 2 Diabetes

Liens